Elevation Wealth Partners
ALGS icon

Elevation Wealth Partners’s Aligos Therapeutics ALGS Stock Holding History

Elevation Wealth Partners’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$23 Hold
4
– – ﹤0.01% 1340
2026
Q2 		$24 Hold
4
– – ﹤0.01% 1301
2026
Q1 		$30 Hold
4
– – ﹤0.01% 1069
2025
Q4 		$38 Hold
4
– – ﹤0.01% 948
2025
Q3 		$40 Hold
4
– – ﹤0.01% 860
2025
Q2 		$29 Hold
4
– – ﹤0.01% 470
2025
Q1 		$33 Hold
4
– – ﹤0.01% 479
2024
Q4 		$160 Hold
4
– – ﹤0.01% 471
2024
Q3 		$35 Hold
4
– – ﹤0.01% 462
2024
Q2 		$35 Hold
4
– – ﹤0.01% 494
2024
Q1 		$98 Hold
4
– – ﹤0.01% 452
2023
Q4 		$75 Hold
4
– – ﹤0.01% 422
2023
Q3 		$75 Hold
4
– – ﹤0.01% 321
2023
Q2 		$98 Hold
4
– – ﹤0.01% 332
2023
Q1 		$88 Buy
+4
New +$153 ﹤0.01% 333

Other funds holding ALGS

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Golden State Wealth Management
Golden State Wealth Management Santa Ana, California $1.1B AUM 19.2% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Elevation Wealth Partners's ALGS Position: Q3 2026 in Review

Elevation Wealth Partners held its Aligos Therapeutics (ALGS) position steady in Q3 2026 at 4 shares worth $23. The position accounts for ﹤0.01% of the portfolio, ranked #1340.

Elevation Wealth Partners first reported a position in ALGS in Q1 2023 and has held it in 15 quarters since. The position peaked at $160 in Q4 2024. 7 funds tracked by Wall St. Rank hold ALGS as of Q3 2026.

  • Elevation Wealth Partners held 4 shares of Aligos Therapeutics worth $23 as of Q3 2026.
  • Elevation Wealth Partners left its Aligos Therapeutics share count unchanged in Q3 2026.
  • Aligos Therapeutics made up ﹤0.01% of Elevation Wealth Partners's portfolio in Q3 2026, its #1340 holding.
  • Elevation Wealth Partners first reported a position in Aligos Therapeutics in Q1 2023 and has held it in 15 quarters since.
  • Elevation Wealth Partners's Aligos Therapeutics position peaked at $160 in Q4 2024.
  • 7 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q3 2026.

Based on Elevation Wealth Partners's 13F filing for Q3 2026, filed 7 Oct 2026.